The U.S. Food and Drug Administration has approved an oral cholesterol-lowering medication that provides an alternative to injectable treatments for patients with persistently elevated cholesterol despite taking statins. Merck's Lipfendra is the first pill designed to block PCSK9, a liver protein that interferes with the body's natural cholesterol removal process. Previously, PCSK9-targeting drugs were available only as injections, a limitation that hindered their use due to cost, insurance barriers, and limited prescribing patterns.
The medication targets patients with dangerously high LDL cholesterol that remains elevated despite standard treatment. While statins reduce cholesterol production in the liver, many patients cannot achieve adequate cholesterol reduction with statins alone and require additional therapy to reach recommended targets and lower their cardiovascular risk.
Two clinical trials supported the approval. In one study of approximately 3,000 high-risk participants taking Lipfendra alongside existing cholesterol medications, patients experienced an LDL reduction exceeding 55% after six months. A second trial showed an average LDL reduction of 59% compared with placebo. Cholesterol-lowering effects remained largely consistent over one year. Dizziness and diarrhea were the most commonly reported side effects, occurring at rates similar to placebo. The medication must be taken on an empty stomach.
The FDA granted approval through its accelerated review program for treatments serving significant public interest. Heart disease remains the leading cause of death in the United States, with elevated LDL cholesterol identified as a primary contributor to heart attacks and strokes. Physicians typically recommend LDL levels of 70 or lower for patients with heart disease or high cholesterol, with even lower targets for those at highest cardiovascular risk.